RT Rapport Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Follow the Rapport Therapeutics, Inc. share price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was filed on 9 September 2026 (Cession). Among the most active insiders: Ceesay Abraham. The full history is openly available.
Analyst consensus: bullish or bearish? Analysts rate Rapport Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 9 September 2026
All Executives65 Thresholds0 Prospectus0 Other0
Declarations 65 total
▼ Chief Executive Officer · Executives · 8 Sept 2026
7,141 shares @ US$45.555 Common Stock SEC:0001193125-26-386436:0
▼ Chief Executive Officer · Executives · 8 Sept 2026
1,069 shares @ US$46.0147 Common Stock SEC:0001193125-26-386436:1
▼ Chief Executive Officer · Executives · 25 Aug 2026
18,921 shares @ US$49.5723 0.040% mcap 17.5% of flow Common Stock SEC:0001193125-26-368285:0
▼ Chief Development Officer · Executives · 24 Aug 2026
13,160 shares @ US$49.9983 0.028% mcap 15.1% of flow Common Stock SEC:0001193125-26-368244:0
▼ Chief Development Officer · Executives · 25 Aug 2026
20,799 shares @ US$50.3111 0.045% mcap 24.0% of flow Common Stock SEC:0001193125-26-368244:1
▼ Chief Development Officer · Executives · 25 Aug 2026
16,201 shares @ US$51.0576 0.036% mcap 19.0% of flow Common Stock SEC:0001193125-26-368244:2
● Officer · Executives · 25 Aug 2026
37,000 shares @ US$49.33 0.079% mcap 73.6% of flow Common SEC144:0001950047-26-008670
● Officer · Executives · 24 Aug 2026
11,472 shares @ US$48.24 0.024% mcap 84.3% of flow Common SEC144:0001950047-26-008594
▼ Chief Development Officer · Executives · 19 Aug 2026
404 shares @ US$49.90 0.0009% mcap 1.1% of flow Common Stock SEC:0001193125-26-359189:0
● Officer · Executives · 19 Aug 2026
2,092 shares @ US$49.01 0.0044% mcap 100.0% of flow Common SEC144:0001950047-26-008426
▼ Chief Executive Officer · Executives · 10 Aug 2026
8,370 shares @ US$46.7479 0.017% mcap 8.9% of flow Common Stock SEC:0001193125-26-346995:1
▼ Chief Executive Officer · Executives · 10 Aug 2026
14,171 shares @ US$45.9736 0.029% mcap 14.9% of flow Common Stock SEC:0001193125-26-346995:0
▼ Chief Executive Officer · Executives · 11 Aug 2026
3,664 shares @ US$46.8988 0.0076% mcap 3.9% of flow Common Stock SEC:0001193125-26-346995:2
▼ Chief Executive Officer · Executives · 11 Aug 2026
19,500 shares @ US$48.0434 0.041% mcap 21.4% of flow Common Stock SEC:0001193125-26-346995:3
▼ Chief Executive Officer · Executives · 11 Aug 2026
5,794 shares @ US$48.6229 0.012% mcap 6.4% of flow Common Stock SEC:0001193125-26-346995:4
▼ Chief Executive Officer · Executives · 27 Jul 2026
2,203 shares @ US$42.107 0.0046% mcap 4.8% of flow Common Stock SEC:0001193125-26-323637:0
▼ Chief Executive Officer · Executives · 27 Jul 2026
7 shares @ US$42.735 0.0000% mcap 0.0% of flow Common Stock SEC:0001193125-26-323637:1
▼ Chief Executive Officer · Executives · 14 Jul 2026
5,481 shares @ US$39.7217 0.011% mcap 11.9% of flow Common Stock SEC:0001193125-26-304786:0
▼ Chief Executive Officer · Executives · 14 Jul 2026
2,729 shares @ US$40.5724 0.0056% mcap 6.1% of flow Common Stock SEC:0001193125-26-304786:1
▼ Chief Executive Officer · Executives · 29 Jun 2026
876 shares Common Stock SEC:0001193125-26-292519:1
▼ Chief Executive Officer · Executives · 29 Jun 2026
7,344 shares Common Stock SEC:0001193125-26-292519:0
● Officer · Executives · 30 Jun 2026
10,000 shares @ US$40.39 0.021% mcap 100.0% of flow Common SEC144:0001950047-26-006648
● Officer · Executives · 29 Jun 2026
99,480 shares @ US$40.39 0.21% mcap 100.0% of flow Common SEC144:0001958244-26-000411
▼ Chief Development Officer · Executives · 17 Apr 2026
20,225 shares @ US$39.9923 0.041% mcap 100.0% of flow Common Stock SEC:0001193125-26-167091:0
▼ 10% Owner · Executives · 17 Apr 2026
426,005 shares @ US$40.317 0.88% mcap 100.0% of flow Common Stock SEC:0001193125-26-167636:0
25 of 65 declarations
Load more (40 remaining) 关于 Rapport Therapeutics, Inc. Rapport Therapeutics, Inc. 是一家专注于开发创新神经系统疾病治疗方法的公司。该公司在 XNAS 市场上市。